Secondly, we have established a prediction model based on the expression of H3K4me3-related lncRNAs, which could provide a better patient enrollment criteria for tumor immunotherapy targeting CD4+ or CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.